520 related articles for article (PubMed ID: 23933801)
1. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
2. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
3. Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Heikkinen T; Korpela T; Fagerholm R; Khan S; Aittomäki K; Heikkilä P; Blomqvist C; Carpén O; Nevanlinna H
Breast Cancer Res Treat; 2013 Aug; 141(1):79-88. PubMed ID: 23974830
[TBL] [Abstract][Full Text] [Related]
4. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.
Tsang JY; Wong KH; Lai MW; Lacambra MD; Ko CW; Chan SK; Lam CC; Yu AM; Tan PH; Tse GM
J Clin Pathol; 2013 Apr; 66(4):291-6. PubMed ID: 23268325
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2010 Jul; 122(1):45-53. PubMed ID: 19701705
[TBL] [Abstract][Full Text] [Related]
6. [Breast cancer classification is evolving].
Penault-Llorca F
Biol Aujourdhui; 2014; 208(4):251-9. PubMed ID: 25840451
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss.
Braun L; Mietzsch F; Seibold P; Schneeweiss A; Schirmacher P; Chang-Claude J; Peter Sinn H; Aulmann S
Mod Pathol; 2013 Sep; 26(9):1161-71. PubMed ID: 23558572
[TBL] [Abstract][Full Text] [Related]
8. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
Temmim L; Baker H; Sinowatz F
Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
[TBL] [Abstract][Full Text] [Related]
10. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
12. P-cadherin and vimentin are useful basal markers in breast cancers.
Tsang JY; Au SK; Ni YB; Shao MM; Siu WM; Hui SW; Chan SK; Chan KW; Kwok YK; Chan KF; Tse GM
Hum Pathol; 2013 Dec; 44(12):2782-91. PubMed ID: 24139214
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
14. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
15. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
16. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
Tas F
Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
[TBL] [Abstract][Full Text] [Related]
18. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
19. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
20. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
